A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma

Future Oncology
M Offidani, Laura Corvatta

Abstract

Monoclonal antibodies (mAb) represent a new frontier to treat newly diagnosed and relapsed-refractory multiple myeloma (MM). Elotuzumab, an mAb targeted SLAM7 in the plasma cells and natural killer cells surface, is the first mAb approved for the treatment of relapsed-refractory MM in combination with lenalidomide and dexamethasone. This approval was the final result of several preclinical and Phase I-II clinical studies leading to ELOQUENT-2 Phase III trial that demonstrated that elotuzumab adds a significant and durable value to standard therapy, paved the way of this new treatment strategy for MM. In this review we will describe elotuzumab mechanisms of action, clinical pharmacology and clinical studies that have led to these developments.

References

Dec 21, 2004·Leukemia Research·Hatsue OgawaraHirokazu Murakami
Aug 10, 2007·British Journal of Haematology·Guy PrattPaul Moss
Apr 22, 2008·Nature Immunology·Eric VivierSophie Ugolini
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric D HsiMarna B Williams
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrzej J JakubowiakKenneth C Anderson
Apr 14, 2012·Blood·Jonathan J KeatsP Leif Bergsagel
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sagar LonialSundar Jagannath
Jul 10, 2012·Haematologica·Roberto J Pessoa de MagalhãesUNKNOWN Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups
Jun 5, 2013·Critical Reviews in Oncology/hematology·André Veillette, Huaijian Guo
Jan 17, 2014·Nature Communications·Niccolo BolliNikhil C Munshi
Apr 2, 2014·The Journal of Experimental Medicine·Luis-Alberto Pérez-QuinteroAndré Veillette
Jul 12, 2014·BioMed Research International·Alessandra RomanoFrancesco Di Raimondo
Oct 8, 2014·Cancer Immunology, Immunotherapy : CII·Balaji BalasaAudie G Rice
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Mar 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacqueline M Genovese, Jonathan S Berek
Mar 20, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Leonid GibianskyManish Gupta
May 2, 2016·Blood Reviews·Ehsan MalekSergio A Giralt
Aug 6, 2016·Therapeutic Advances in Hematology·Hila Magen, Eli Muchtar
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paola NeriSagar Lonial
Jan 6, 2017·Cancer Treatment Reviews·Francesca PavanelloMichele Ghielmini
Jan 14, 2017·Haematologica·Paula Rodríguez-OteroJesús F San Miguel
Jan 24, 2017·Expert Review of Hematology·Jean-Samuel BoudreaultPhilippe Moreau

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00742560
NCT00726869
NCT01478048
NCT01632150
NCT01239797
NCT02252263
NCT03023527
NCT03227432
NCT02718833
NCT03155100

Software Mentioned

Elo
Rd

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sagar LonialSundar Jagannath
Human Vaccines & Immunotherapeutics
Sabarinath Venniyil RadhakrishnanDjordje Atanackovic
© 2022 Meta ULC. All rights reserved